< DevicesKenko Imalytics develops a family of MRI-based clinical devices that transform multiparametric MRI into quantitative, explainable imaging biomarkers, bringing clarity, consistency, and confidence to cancer care.
Built on a shared scientific foundation, Kenko Imalytics devices convert complex imaging into physiologically grounded insight that clinicians can interpret, trust, and act upon. Each device is designed for a specific clinical indication, supporting radiologists and multidisciplinary teams in understanding tumour behaviour and making more informed decisions across the oncology pathway.
Kenko Breast AI+ is the flagship device of Kenko Imalytics, designed to support radiologists in breast MRI interpretation by transforming complex multiparametric imaging into interpretable, quantitative biomarker maps.
It provides objective, physiology-linked insight into tumour behaviour, including vascularisation, cellularity, and heterogeneity. This enables more accurate lesion characterisation, reduces variability, and strengthens confidence in high-stakes clinical decisions. It also allows clinicians to differentiate the most aggressive regions within a lesion, supporting more precise biopsy targeting and treatment planning.
Integrated into routine clinical workflows, Kenko Breast AI+ supports faster reading, clearer reporting, and more effective multidisciplinary collaboration, delivering measurable value for clinicians, hospitals, and patients.
Kenko Prostate extends the Kenko Imalytics approach to prostate cancer, transforming multiparametric MRI into quantitative, explainable imaging biomarkers that support clearer interpretation and more consistent clinical decisions.
By integrating perfusion, diffusion, and anatomical information, the device provides structured, objective insight into tumour presence, localisation, and biological behaviour, helping radiologists reduce uncertainty, improve risk stratification, and strengthen multidisciplinary alignment. This enables clinicians to move beyond detection toward a clearer understanding of clinically significant disease.
The result is more efficient, evidence-based prostate cancer care, with greater confidence in clinically significant cases.
Bringing greater clarity to tumour staging and surgical planning in rectal cancer through quantitative MRI biomarkers
Supporting confident characterisation of complex liver lesions through quantitative, biomarker-driven MRI interpretation
Enhancing assessment of tumour invasion and progression in bladder cancer through objective, biomarker-based insight
Kenko Imalytics advances MRI from detection toward a deeper, quantitative understanding of tumour behaviour.
Through a growing portfolio of MRI-based clinical devices, Kenko Imalytics brings clarity to complexity, enabling clinicians to interpret, communicate, and act with greater confidence at every stage of the oncology pathway.
Your login details have been sent to the email address linked to your authorised account. Please
follow the instructions included in that email to
access the platform securely.
Thank you.
